Abstract
Oxaliplatin is widely used as a chemotherapeutic agent for treating unresectable or metastatic gastrointestinal tract cancer, such as gastric cancer and colorectal cancer. The toxic effects commonly associated with oxaliplatin include neuropathy, myelosuppression, hypersensitivity reactions, and chemotherapy-induced hepatotoxicity. However, oxaliplatin-induced hemolytic anemia has rarely been reported in the medical literature. Herein, we describe a case of oxaliplatin-induced autoimmune hemolytic anemia in a patient with metastatic gastric cancer who received biweekly oxaliplatin-based chemotherapy that included fluorouracil and folinic acid. He presented with acute-onset anemia and acute renal failure shortly after the 25th course of oxaliplatin-based chemotherapy. A positive direct and indirect Coombs test and a good response to steroid therapy suggested the diagnosis of autoimmune hemolytic anemia. Afterwards, the patient was switched to an oral 5-fluorouracil agent, TS-1, for further treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
